Clinical Trial Update: Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic interaction study to evaluate how daclatasvir (BMS-790052) affects the plasma levels of Ortho Tri-Cyclen in healthy female subjects has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Ortho Tri-Cyclen (ethinyl estradiol / norgestimate)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2015-09-16